Article Details
Retrieved on: 2025-07-02 11:29:38
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The company's focus on monoclonal antibodies (mAbs) like PEMGARDA® and VYD2311 could unlock a high-margin therapeutic opportunity while catalyzing ...
Article found on: www.ainvest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here